PMID- 31233150
OWN - NLM
STAT- MEDLINE
DCOM- 20200115
LR  - 20200115
IS  - 2325-8179 (Electronic)
IS  - 2325-8160 (Linking)
VI  - 50
IP  - 6
DP  - 2019 Jun 1
TI  - Neurodevelopmental Outcomes Comparing Bevacizumab to Laser for Type 1 ROP.
PG  - 337-343
LID - 10.3928/23258160-20190605-01 [doi]
AB  - BACKGROUND AND OBJECTIVE: To evaluate neurodevelopmental outcomes among infants 
      treated for retinopathy of prematurity (ROP) at the authors' institution. 
      PATIENTS AND METHODS: Before-and-after retrospective chart reviews identified 40 
      infants treated with laser and 46 treated with primary intravitreal bevacizumab 
      (IVB). Primary outcomes were death, hearing loss, bilateral visual impairment 
      (BVI), and cerebral palsy (CP); odds ratios (ORs) were calculated to determine 
      factors associated with CP. Secondary outcomes were mean Bayley Scales of Infant 
      and Toddler Development, Third Edition (BSID-III) scores. RESULTS: Overall, there 
      were no significant differences in primary outcome measures by treatment group. 
      However, adjusted odds of BVI were significantly higher with laser compared to 
      IVB (OR = 13.1; P = .038). Although IVB was not associated with CP, both 
      hydrocephalus and BVI were strongly correlated with CP. Mean Bayley-III scores 
      were similar when comparing nine laser-treated infants to 13 IVB-treated infants. 
      CONCLUSIONS: Visual outcomes are an important aspect of neurodevelopment. IVB was 
      not associated with severe developmental disabilities and may protect against 
      vision loss in this analysis. [Ophthalmic Surg Lasers Imaging Retina. 
      2019;50:337-343.].
CI  - Copyright 2019, SLACK Incorporated.
FAU - Rodriguez, Sarah Hilkert
AU  - Rodriguez SH
FAU - Peyton, Colleen
AU  - Peyton C
FAU - Lewis, Katherine
AU  - Lewis K
FAU - Andrews, Bree
AU  - Andrews B
FAU - Greenwald, Mark J
AU  - Greenwald MJ
FAU - Schreiber, Michael D
AU  - Schreiber MD
FAU - Msall, Michael E
AU  - Msall ME
FAU - Blair, Michael P
AU  - Blair MP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ophthalmic Surg Lasers Imaging Retina
JT  - Ophthalmic surgery, lasers & imaging retina
JID - 101599215
RN  - 0 (Angiogenesis Inhibitors)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/adverse effects/*therapeutic use
MH  - Bevacizumab/adverse effects/*therapeutic use
MH  - Cerebral Palsy/epidemiology
MH  - Female
MH  - Hearing Loss/epidemiology
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - Intravitreal Injections
MH  - Laser Coagulation/*methods
MH  - Male
MH  - Odds Ratio
MH  - *Retinopathy of Prematurity/drug therapy/mortality/surgery
MH  - Retrospective Studies
MH  - Vision, Low/epidemiology
EDAT- 2019/06/25 06:00
MHDA- 2020/01/16 06:00
CRDT- 2019/06/25 06:00
PHST- 2018/06/15 00:00 [received]
PHST- 2019/01/03 00:00 [accepted]
PHST- 2019/06/25 06:00 [entrez]
PHST- 2019/06/25 06:00 [pubmed]
PHST- 2020/01/16 06:00 [medline]
AID - 10.3928/23258160-20190605-01 [doi]
PST - ppublish
SO  - Ophthalmic Surg Lasers Imaging Retina. 2019 Jun 1;50(6):337-343. doi: 
      10.3928/23258160-20190605-01.